Publications

Poster presented at: 2016 International Congress of the World Federation of Hemophilia, Orlando, FL July 27, 2016  Poster Num: 160 -PP-W  Title:  Diagnosis of platelet disorders despite normal platelet aggregations  Authors: Janice Kuhn , Melinda Nolte, Erika J. Martin, Gita V. Massey, William Gunning.

 

Poster presented at:  2016International Congress of the World Federation of Hemophilia, Orlando, FL July 25, 2016  Poster Num: 097-PP-M  Title:  PF-06741086, a monoclonal antibody with Tissue Factor Pathway Inhibitor (TFPI) neutralizing activity, improves coagulation parameters in global hemostatic assays in hemophilic whole blood and plasma  Authors: Sunita Patel-Hett, Erika J. Martin, Bassem M. Mohammed, Swapnil Rakhe, Melinda Nolte, Janice Kuhn, J. Christian Barrett, Debra D. Pittman, Donald Brophy, John E. Murphy

 

Gunasekera D, Ettinger RA, Nakaya Fletcher S, James EA, Liu M, Barrett JC, Withycombe J, Matthews DC, Epstein MS, Hughes RJ, Pratt KP; Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators. Factor VIII gene variants and inhibitor risk in African American hemophilia A patients. Blood. 2015;126:895-904. doi: 10.1182/blood-2014-09-599365. 

 

Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, Miller CH; Hemophilia Inhibitor Research Study Investigators; Hemophilia Inhibitor Research Study Investigators. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.  J Thromb Haemost. 2015;13:47-53.  doi: 10.1111/jth.12768.

 

Geary MK, McGeady L, Dunn L, Pennick L, Johnson M, Stolfi A; The Demographics of the United States Hemophilia Treatment Center Social Workers: The Results of a National Survey.  Haemophilia. 2014;20:500-5. doi: 10.1111/hae.12354. 

 

Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM; Hemophilia Inhibitor Research Study Investigators. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost. 2013;11:1300-9. doi: 10.1111/jth.12259.

 

Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT; Haemophilia Inhibitor Research Study Investigators.  A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.  Haemophilia. 2014;20:230-7.  doi: 10.1111/hae.12302. 

 

Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM; Hemophilia Inhibitor Research Study Investigators.  Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost. 2013;11:1300-9. doi: 10.1111/jth.12259.

 

Pandey GS, Yanover C, Miller-Jenkins LM, Garfield S, Cole SA, Curran JE, Moses EK, Rydz N, Simhadri V, Kimchi-Sarfaty C, Lillicrap D, Viel KR, Przytycka TM, Pierce GF, Howard TE, Sauna ZE; PATH (Personalized Alternative Therapies for Hemophilia) Study Investigators.   Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia.  Nat Med. 2013;19:1318-24. doi: 10.1038/nm.3270.

 

Al Hawaj MA, Martin EJ, Venitz J, Barrett JC, Kuhn JG, Nolte ME, Brophy DF.

Haemophilia. Monitoring rFVIII prophylaxis dosing using global haemostasis assays.  Haemophilia. 2013;19:409-14.  doi: 10.1111/hae.12110.

 

Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM; Hemophilia Inhibitor Research Study Investigators. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost. 2012;10:1055-61. doi: 10.1111/j.1538-7836.2012.04705.x.

 

Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Craig Hooper W; Hemophilia Inhibitor Research Study Investigators. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia. 2012;18:375-82. doi: 10.1111/j.1365-2516.2011.02700.x.

 

Brophy DF, Martin EJ, Barrett JC, Nolte ME, Kuhn JG, Pelzer H, Agersø H, Carr ME, Ezban M, Hedner U. Monitoring rFVIIa 90 µg Kg-1: Comparing Laboratory Response of Using Various Whole Blood Assays Over 6 h. Haemophilia. 2011;17:949-57. doi: 10.1111/j.1365-2516.2011.02492.x.

 

Brophy DF, Martin EJ, Barrett JC, Nolte ME, Kuhn JG, Ezban M, Hedner U. Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays. Blood Coagul and Fibrinolysis. 2011;22:541-6.  doi: 10.1097/MBC.0b013e328348d9e5.

 

Agersø H, Brophy DF, Martin EJ, Pelzer H, Carr ME, Hedner U, Ezban M. Factor VIIa cleared principally by antithrombin following IV administration in haemophilia patients. J Thromb Haemost. 2011;9:333-8.  doi: 10.1111/j.1365-2516.2011.02492.x.

 

Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Barrett JC, Ezban M. Factor VIIa analog (NN1731) has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A. Blood Coagul Fibrinolysis.2010;21:539-46. doi: 10.1097/MBC.0b013e32833b63e9.

 

MCV Campus